Introduction
Methods
Study population
Assessments
Statistical analysis
Results
Total number of patients (n) | 99 |
---|---|
Combined SAA and CRP measurements (n) | 381 |
Number of visits with combined measurement per patient, median (minimum-maximum) | 3 (1–13) |
Visits while on specific medication, n (%) | Prednisone 28 (7.3%), Anakinra 59 (15.5%), Canakinumab 67 (17.6%), Tocilizumab 6 (1.6%), Colchicine 166 (43.6%), Humira 3 (0.8%), antibiotics 4 (1%) |
Male sex, n (%) | 56 (57%) |
Age (years), median (interquartile range) | 21 (11–38) |
BMI (kg/m2), mean (±SD) | 22.53 (±5.75) |
Autoinflammatory diagnoses (n) | FMF (45), CAPS (9), sJIA (5), Schnitzler syndrome (4), TRAPS (3), hidradenitis suppurativa (3), adult onset still’s disease (AOSD) (3), Behcet disease (2), PFAPA (2), MKD (2), PAPA (1), DADA2 (1) and unclassified autoinflammatory diagnosis (19) |
AA amyloidosis present, n (%) | Yes 11 (11.1%), No 88 (88.9%%) |
Ethnicity, n (%) | Caucasian 45 (45.9%), Arabic 33 (33.7%), Armenian 13 (13.1%), Asian 2 (2%), Afro-American 1 (1%), Russian 1 (1%), Georgian 1 (1%), unknown 3 (2%). |
SAA (rho=) | Significance (p-value) | CRP (rho=) | Significance (p-value) | N | |
---|---|---|---|---|---|
CRP (mg/L) | 0.755 | < 0.001* | 1 | – | 381 |
ESR (mm/h) | 0.550 | < 0.001* | 0.620 | < 0.001* | 344 |
Granulocytes (n) | 0.291 | < 0.001* | 0.396 | < 0.001* | 297 |
Ferritin (ug/L) | 0.327 | 0.002* | 0.491 | < 0.001* | 85 |
Lymphocytes (n) | −0.173 | 0.003* | −0.161 | 0.006* | 296 |
BMI (kg/m2) | 0.255 | 0.017* | 0.343 | 0.001* | 87 |
Age (years) | 0.221 | < 0.001* | 0.404 | < 0.001* | 380 |
SAA above 4 mg/L | SAA above 10 mg/L | |||||
---|---|---|---|---|---|---|
Yes | No | Yes | No | |||
CRP above 5 mg/L | Yes | 76 (85.4%) | 48 (16.4%) | 124 (32.5%) | 68 (91.9%) | 56 (18.2%) |
No | 13 (14.6%) | 244 (83.6%) | 257 (67.5%) | 6 (8.1%) | 251 (81.8%) | |
Total | 89 (23.3%) | 292 (76.7%) | 381 | 74 (19.4%) | 307 (80.6%) |
All measurements | True positives | False positives | True negatives | False negatives | |
---|---|---|---|---|---|
Number of patients (n) | 99 | ||||
Total number of visits (n) | 381 | 76 | 48 | 244 | 13 |
Age (years) median (IQR) | 21 (11–38) | 23 (10–35) | 36 (23–57) (p = 0.240) | 18 (9–30) | 17 (15–58) (p = 0.531) |
BMI (kg/m2), mean (±SD) | 22.53 (±5.75) | 21.96 (±4.56) | 28.16 (±7.25) (p < 0.001)* | 21.80 (±5.60) | 23.77 (±0.34) (p = 0.875) |
CRP values mg/L, median (IQR) | 2.00 (0.40–9.00) | 29 (12.00–54.00) | 10 (7.00–11.00) | 0.70 (0.30–1.80) | 2.70 (1.40–4.25) |
SAA values mg/L, median (IQR) | 1.00 (0.50–4.50) | 43.50 (15.75–109.50) | 2.00 (1.00–4.00) | 1.00 (1.00–1.00) | 10.00 (7.00–39.00) |
Visits with medication usage, n (%) | Colchicine 166 (43.6%), | Colchicine 27 (35.5%), | Colchicine 20 (41.7%), | Colchicine 115 (47.1%), | Colchicine 4 (30.8%), |
Canakinumab 67 (17.6%), | Canakinumab 8 (10.5%), | Canakinumab 9 (18.8%), | Canakinumab 49 (20.1%), | Canakinumab 1 (7.7%), | |
Anakinra 59 (15.5%), | Anakinra 16 (21.1%), | Anakinra 8 (16.6%), | Anakinra 33 (13.5%), | Anakinra 2 (15.4%), | |
Prednisone 28 (7.3%), | Prednisone 11 (14.5%), | Prednisone 1 (2.1%), | Prednisone 13 (5.3%), | Prednisone 3 (23.1%), | |
Tocilizumab 6 (1.6%), | Tocilizumab 0, (0%) | Tocilizumab 0, (0%) | Tocilizumab 6 (2.5%), (0%) | Tocilizumab 0, (0%) | |
Humira 3 (0.8%), | Humira 0, (0%) | Humira 0, (0%) | Humira 3 (1.2%), | Humira 0, (0%) | |
antibiotics 4 (1%), | antibiotics 1 (1.3%), | antibiotics 2 (4.2%), | antibiotics 1 (0.4%), | antibiotics 0, (0%) | |
no medication 48 (12.6%) | no medication 13 (17.1%) | no medication 0 (0%) | no medication 24 (9.8%) | no medication 4 (30.8%) | |
Conclusion of visit based on expert opinion and ADAI, n (%) | Flare up AID 40 (10%), | Flare up AID 22 (28.9%), | Flare up AID 7 (15%), | Flare up AID 11 (4.5%), | remission 13 (100%) |
remission 320 (84%), | remission 45 (59.2%), | remission 37 (77%), | Remission 225 (92.6%), | ||
infection 8 (2%) | infection 4 (5.3%), | infection 2 (4%), | Infection 2 (0.8%), | ||
unknown 13 (3%) | Unknown 5 (6.6%) | Unknown 2 (4%) | unknown 6 (2.5%) |
Univariate B (95% CI) | p-value | Multivarariate B (95% CI) | p-value | |
---|---|---|---|---|
CRP (mg/L) | 0.020 (0.018; 0.022) | < 0.001* | 0.017 (0.015; 0.019) | < 0.001 |
Age (years) | 0.006 (0.002; 0.009) | 0.002* | – | n.s. |
BMI (kg/m2) | 0.007 (−0.021; 0.035) | 0.671 | ||
Sex (m/f) | 0.020 (−0.284; 0.324) | 0.896 | ||
AA amyloidosis (no/yes) | 0.032 (−0.241; 0.034) | 0.891 | ||
ESR (mm/h) | 0.015 (0.013; 0.018) | < 0.001* | 0.005 (0.002; 0.007) | < 0.001 |
Lymphocytes (10^9/l) | −0.184 (− 0.228; − 0.068) | < 0.001* | – | n.s. |
Granulocytes (10^9/l) | 9.119 (5.253; 12.985) | < 0.001* | – | n.s. |
Ferritin (ug/L) | 0.005 (0.003; 0.007) | < 0.001* | – | n.s. |
Antibiotics (no/yes) | 0.282 (−0.394; 0.958) | 0.413 | ||
Prednisone (no/yes) | 0.416 (0.150; 0.683) | 0.002* | 0.232 (0.049; 0.415) | 0.013 |
Anakinra (no/yes) | 0.143 (−0.051; 0.338) | 0.149 | ||
Canakinumab (no/yes) | −0.168 (− 0.353; 0.016) | 0.074 | ||
Colchicine (no/yes) | −0.074 (− 0.217; 0.068) | 0.306 | ||
Medication taken during attack (no/yes) | −0.163(− 0.534;0.208) | 0.387 |